Tonix Pharmaceuticals reports Q2 EPS ($3.86)

Reports Q2 revenue $1.998M vs $2.208M last year. “With the U.S. Food and Drug Administration Prescription Drug User Fee Act goal date of August 15, for TNX-102 SL for fibromyalgia, we are excited about the potential to make this important new therapy available to patients in the fourth quarter of this year,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals (TNXP). “FDA considers fibromyalgia a serious condition and awarded TNX-102 SL Fast Track designation last year. There has been no new treatment for this debilitating condition approved in over 16 years. Additionally, our RESILIENT Phase 3 study results were recently published in the peer-reviewed journal, Pain Medicine.”